Ginkgo Bioworks Holdings, Inc. (DNA)
| Market Cap | 525.74M |
| Revenue (ttm) | 180.61M |
| Net Income (ttm) | -339.55M |
| Shares Out | 56.84M |
| EPS (ttm) | -6.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,420,103 |
| Open | 9.90 |
| Previous Close | 9.21 |
| Day's Range | 9.01 - 9.95 |
| 52-Week Range | 5.00 - 17.58 |
| Beta | 1.55 |
| Analysts | Strong Sell |
| Price Target | 9.00 (-2.7%) |
| Earnings Date | Nov 6, 2025 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms... [Read more]
Financial Performance
In 2024, Ginkgo Bioworks Holdings's revenue was $227.04 million, a decrease of -9.71% compared to the previous year's $251.46 million. Losses were -$547.03 million, -38.73% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DNA stock is "Strong Sell" and the 12-month stock price target is $9.0.
News
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
BOSTON , Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory...
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has bee...
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year ...
Ginkgo Bioworks: Not There Yet
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and oper...
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. ( DNA) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting...
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third qu...
Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON , Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA...
Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture
BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of ...
Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON , Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it...
Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases BOSTON , Oct. 23, 2025 /PRNewswire/ ...
Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions
BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, deriva...
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry
BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entere...
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to suppo...
Ginkgo Bioworks: Sell The Recent Rally
Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates h...
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason K...
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON , Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA,...
Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON , July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the le...
Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy
Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended exploration of bioconomy-relevant microbes BOSTON , July 30, 2025 /PRNewswire/ ...
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors
Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasets BOSTON , July 17, 2025 /PRNewswire/ -- Ginkgo Biow...
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmy...
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Foun...
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distribut...
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficienc...